Optimization and Construction of Human Insulin-like Growth Factor 1 Gene
Publish place: دومین کنفرانس بین المللی پژوهش در علوم و تکنولوژی
Publish Year: 1394
نوع سند: مقاله کنفرانسی
زبان: English
View: 546
This Paper With 7 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
CRSTCONF02_295
تاریخ نمایه سازی: 21 شهریور 1395
Abstract:
Background: Laron syndrome, is a disease that treated by IGF-1. This protein is a single chain and has three disulfide bonds. People with Laron syndrome have low rates of cancer and diabetes, although they appear to be at increased risk of casual death due to their stature. IGF-1 is synthesized by many tissues and is secreted from liver as an endocrine hormone which is transmitted to other tissues. IGF-1 is responsible for cell differentiation, transformation, suppression of apoptosis, cell cycle progression, cell proliferation and differentiation. Expression system, the igf-1 gene, codon adaptation index (CAI) and GC contents are very critical for the large scale production of this protein. Current study was aimed to Optimization and Construction of human Insulin-like Growth Factor 1 Gene in E. coli DH5α.Material and Methods: we used DNA2 and ProtParam softwares for designing the best form to produce IGF-1. First the coding sequence was verified and then synthesized. For confirmation of the pUC18-IGF-1, sequencing test was carried out using M13 reverse primer. Finally it was inserted into the cloning site of pUC18.vector. Results: After coding optimization, the CAI rate was increased from 84 % to 90% and GC content from 55.07 % to 56.62%. The presence of the band near 225bp resulted from enzymatic digestion with two restriction enzymes demonstrates the correct cloning of the recombinant vectors in the cloning site of pUC18 cloning vector.Conclusion: According to software and experimental analysis, the designed sequence probably in the best form could be used for production of recombinant protein.
Keywords:
Authors
Hamidreza Iranpoor
M.Sc. in Medical Biotechnology, Department of Medical Biotechnology, Faculty of Advanced Technologies In Medicine, Golestan University of Medical Science, Gorgan, Iran
Venus Vatankhah
MD, Faculty of Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Masoud Lotfizadeh
Assistant Professor, Department of Health Education, Faculty of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran.